Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for ASD in Children and Adolescents
NCT03900923Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in Autism Spectrum Disorder (ASD), sponsored by NYU Langone Health. Primary endpoint: Clinical Global Impression Scale-Improvement at Week 6. Started Mar 2019; status: completed.
02
Drugs
cannabidiol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03900923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900923.